Oct. 29 is Global PSC Awareness Day, and advocates around the world are joining forces to shine a light on primary sclerosing cholangitis (PSC)…
News
CHOLESTASIS
News2 simple nutrients may be effective new screening tool for ICP
A new study has identified two dietary nutrients, choline and dimethylglycine, as effective potential biomarkers for diagnosing and monitoring intrahepatic cholestasis of pregnancy (ICP).
FATTY LIVER DISEASE
NewsLong-term ketogenic diet may cause fatty liver disease, per mouse study
A long-term ketogenic diet, which favors fats over carbs, may promote weight loss, but it can also cause fatty liver disease and blood sugar…
BILIARY ATRESIA
NewsPotential biliary atresia treatment AX-0810 to enter clinical testing
AX-0810, an experimental medication Proqr Therapeutics is developing for biliary atresia and another liver disease called primary sclerosing cholangitis (PSC), is about to…
Kezar Life Sciences has hit a roadblock in plans to develop zetomipzomib, its experimental treatment for autoimmune hepatitis (AIH). The company has…
CHOLANGITIS
NewsSeladelpar approved in Canada as Lyvdelzi to treat adults with PBC
Health Canada has conditionally approved Gilead Sciences’ seladelpar — to be marketed in the country under the brand name Lyvdelzi — as a second-line…
CHOLESTASIS
NewsItching was main sign of teen’s liver disease: Case report
Itching was the main symptom leading to the diagnosis of progressive familial intrahepatic cholestasis (PFIC) type 3 in a teenage boy in Portugal, a…
FATTY LIVER DISEASE
NewsNew Helix dataset aims to accelerate liver disease research
A new dataset from genomics company Helix aims to accelerate research into metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease.
ALAGILLE SYNDROME
NewsLivmarli eases Alagille teen’s itch following liver transplant issues
Treatment with Livmarli (maralixibat) quickly and safely reduced severe itching in a 16-year-old boy with Alagille syndrome after his transplanted liver started to malfunction,…
A Phase 1 clinical trial testing PBGENE-HBV, a gene-editing therapy for chronic hepatitis B, is now recruiting patients at Massachusetts General Hospital in…
Recent Posts
- For girl in Asia, limited access to genetic testing delayed an Alagille diagnosis
- FDA gives bepirovirsen priority review for chronic hepatitis B
- Starting disease marker levels may shape Iqirvo response in PBC
- The possibility for liver function to improve brings me hope
- New mouse model could help guide PFIC3 treatment research